Study: Extrapolation of drug indications from study populations by FDA is ‘common’
Regulatory NewsJeff Craven
Biologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsProduct LifecycleRegulatory NewsJeff CravenBiologics/ biosimilars/ vaccinesBiotechnologyClinical TrialsNorth AmericaPharmaceuticalsProduct Lifecycle